Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · IEX Real-Time Price · USD
12.36
-0.09 (-0.72%)
At close: Jul 19, 2024, 4:00 PM
12.35
-0.01 (-0.08%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

Pliant Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Ending
CurrentDec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Market Capitalization
7461,085943487806
Market Cap Growth
-42.75%15.09%93.72%-39.64%-
Enterprise Value
316600627293529
PE Ratio
--6.72-7.64-5.00-19.41
PS Ratio
3006.56686.5397.3264.2519.28
PB Ratio
1.702.293.012.442.85
P/FCF Ratio
-7.57-9.25-9.78-6.29-20.77
P/OCF Ratio
-7.71-9.32-9.96-6.45-21.63
EV/Sales Ratio
1275.85379.9864.7538.7112.66
EV/EBITDA Ratio
-2.84-3.85-5.28-3.12-13.16
EV/EBIT Ratio
-2.77-3.75-5.12-3.01-12.74
EV/FCF Ratio
-3.95-5.12-6.51-3.79-13.64
Debt / Equity Ratio
0.120.020.050.04-
Debt / EBITDA Ratio
-0.33-0.07-0.13-0.08-
Debt / FCF Ratio
-0.46-0.10-0.16-0.09-
Quick Ratio
15.9217.3813.9312.0424.67
Current Ratio
16.1217.7214.2312.4425.07
Asset Turnover
00.000.040.030.15
Interest Coverage
-120.79-126.34-154.91--
Return on Equity (ROE)
-35.10%-31.20%-50.80%-41.90%-19.90%
Return on Assets (ROA)
-31.80%-29.00%-44.50%-39.40%-14.80%
Return on Capital (ROIC)
-39.52%-37.97%-38.64%-47.29%-14.71%
Earnings Yield
-22.90%-14.87%-13.08%-19.99%-5.15%
FCF Yield
-15.91%-10.81%-10.23%-15.91%-4.81%
Buyback Yield / Dilution
-7.36%-39.75%-17.21%-67.94%-1214.82%
Total Shareholder Return
-7.36%-39.75%-17.21%-67.94%-1214.82%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).